Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates.

Literature DB >> 27141378

Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates.

Giulia Di Lullo¹, Magda Marcatti², Maria Pia Protti¹.

Abstract

We recently reported that in multiple myeloma increased Th22 cell frequencies correlate with poor prognosis. Here we show that within the same patients' cohort Th17 cells associate with bone disease and not with prognosis. Thus, we propose that Th22 and Th17 cells play non-redundant roles in multiple myeloma and constitute independent therapeutic targets.

Entities: Disease Species

Keywords: BM mesenchymal stromal cells; BM microenvironment; IL-13; IL-17; IL-22; Th17 cells; Th22 cells; bone disease; disease prognosis; multiple myeloma

Year: 2015 PMID： 27141378 PMCID： PMC4839310 DOI： 10.1080/2162402X.2015.1093278

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

30 in total

Review 1. Multiple myeloma.

Authors: Antonio Palumbo; Kenneth Anderson
Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245

2. International staging system for multiple myeloma.

Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544

Review 3. Interleukin-22: immunobiology and pathology.

Authors: Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal: Annu Rev Immunol Date: 2015-02-11 Impact factor: 28.527

4. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation.

Authors: Marco Tucci; Stefania Stucci; Annalisa Savonarola; Sabino Ciavarella; Paola Cafforio; Franco Dammacco; Franco Silvestris
Journal: Br J Haematol Date: 2013-04-18 Impact factor: 6.998

5. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells.

Authors: Sara Trifari; Charles D Kaplan; Elise H Tran; Natasha K Crellin; Hergen Spits
Journal: Nat Immunol Date: 2009-07-05 Impact factor: 25.606

6. Clinical significance of interleukin-22 in multiple myeloma.

Authors: George Tsirakis; Constantina A Pappa; Anna Kolovou; Maria Kokonozaki; Ioannis Neonakis; Michael G Alexandrakis
Journal: Hematology Date: 2014-07-24 Impact factor: 2.269

Review 7. The role of regulatory T cells and TH17 cells in multiple myeloma.

Authors: Walter M T Braga; Djordje Atanackovic; Gisele W B Colleoni
Journal: Clin Dev Immunol Date: 2012-03-27

8. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.

Authors: Kojiro Sato; Ayako Suematsu; Kazuo Okamoto; Akira Yamaguchi; Yasuyuki Morishita; Yuho Kadono; Sakae Tanaka; Tatsuhiko Kodama; Shizuo Akira; Yoichiro Iwakura; Daniel J Cua; Hiroshi Takayanagi
Journal: J Exp Med Date: 2006-11-06 Impact factor: 14.307

Review 9. Th17 cells in cancer: the ultimate identity crisis.

Authors: Stefanie R Bailey; Michelle H Nelson; Richard A Himes; Zihai Li; Shikhar Mehrotra; Chrystal M Paulos
Journal: Front Immunol Date: 2014-06-17 Impact factor: 7.561

10. IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression.

Authors: Yuanyuan Sun; Jing Pan; Shudan Mao; Jieping Jin
Journal: PLoS One Date: 2014-12-09 Impact factor: 3.240

7 in total

1. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

Authors: Arianna Calcinotto; Arianna Brevi; Marta Chesi; Roberto Ferrarese; Laura Garcia Perez; Matteo Grioni; Shaji Kumar; Victoria M Garbitt; Meaghen E Sharik; Kimberly J Henderson; Giovanni Tonon; Michio Tomura; Yoshihiro Miwa; Enric Esplugues; Richard A Flavell; Samuel Huber; Filippo Canducci; Vincent S Rajkumar; P Leif Bergsagel; Matteo Bellone
Journal: Nat Commun Date: 2018-12-03 Impact factor: 14.919

2. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

Authors: Subhayan Chattopadhyay; Hauke Thomsen; Pankaj Yadav; Miguel Inacio da Silva Filho; Niels Weinhold; Markus M Nöthen; Per Hoffman; Uta Bertsch; Stefanie Huhn; Gareth J Morgan; Hartmut Goldschmidt; Richard Houlston; Kari Hemminki; Asta Försti
Journal: Commun Biol Date: 2019-03-04

3. Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Authors: Giulia Di Lullo; Magda Marcatti; Silvia Heltai; Cristina Tresoldi; Anna Maria Paganoni; Claudio Bordignon; Fabio Ciceri; Maria Pia Protti
Journal: Front Immunol Date: 2019-01-21 Impact factor: 7.561

Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates.

Review 1. Multiple myeloma.

2. International staging system for multiple myeloma.

Review 3. Interleukin-22: immunobiology and pathology.

4. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation.

5. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells.

6. Clinical significance of interleukin-22 in multiple myeloma.

Review 7. The role of regulatory T cells and TH17 cells in multiple myeloma.

8. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.

Review 9. Th17 cells in cancer: the ultimate identity crisis.

10. IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression.

1. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

2. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

3. Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Review 4. Treg and Oligoclonal Expansion of Terminal Effector CD8⁺ T Cell as Key Players in Multiple Myeloma.

Review 5. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.

6. High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients.

7. Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma.

Review 1. Multiple myeloma.

Review 3. Interleukin-22: immunobiology and pathology.

Review 7. The role of regulatory T cells and TH17 cells in multiple myeloma.

Review 9. Th17 cells in cancer: the ultimate identity crisis.

Review 4. Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma.

Review 5. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.

Review 4. Treg and Oligoclonal Expansion of Terminal Effector CD8⁺ T Cell as Key Players in Multiple Myeloma.